T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.01B |
| 2 |
Broadcom
AVGO
|
+$1.49B |
| 3 |
GE Vernova
GEV
|
+$1.19B |
| 4 |
International Paper
IP
|
+$1.05B |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$952M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.31B |
| 2 |
Constellation Energy
CEG
|
+$1.94B |
| 3 |
Qualcomm
QCOM
|
+$1.74B |
| 4 |
NVIDIA
NVDA
|
+$1.71B |
| 5 |
Salesforce
CRM
|
+$1.5B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.98% |
| 2 | Healthcare | 14.89% |
| 3 | Financials | 10.35% |
| 4 | Consumer Discretionary | 10.11% |
| 5 | Communication Services | 9.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1151
Restaurant Brands International
QSR
$26.7B
| $7.19M | ﹤0.01% |
102,158
-6,706
| -6% | -$479K |
|
1152
Wave Life Sciences
WVE
$1.02B
| $7.18M | ﹤0.01% |
1,439,271
-421,983
| -23% | -$2.41M |
|
|
PARA
1153
DELISTED
Paramount Global Class B
PARA
| $7.17M | ﹤0.01% |
690,547
+20,132
| +3% | +$236K |
|
1154
Applied Industrial Technologies
AIT
$13.2B
| $7.15M | ﹤0.01% |
36,846
+14,239
| +63% | +$2.72M |
|
1155
Royalty Pharma
RPRX
$26.1B
| $7.13M | ﹤0.01% |
270,452
+8,722
| +3% | +$242K |
|
1156
Pacira BioSciences
PCRX
$924M
| $7.13M | ﹤0.01% |
249,144
-82,876
| -25% | -$2.36M |
|
1157
Insight Enterprises
NSIT
$4.6B
| $7.11M | ﹤0.01% |
35,848
-373
| -1% | -$72.5K |
|
1158
Banc of California
BANC
$3.11B
| $7.07M | ﹤0.01% |
553,382
+222,306
| +67% | +$3.07M |
|
|
JHG
1159
DELISTED
Janus Henderson
JHG
| $7.05M | ﹤0.01% |
209,243
+557
| +0.3% | +$18.3K |
|
1160
iShares Russell 1000 Growth ETF
IWF
$129B
| $6.93M | ﹤0.01% |
76,048
-37,860
| -33% | -$3.23M |
|
1161
Alto Neuroscience
ANRO
$1.26B
| $6.9M | ﹤0.01% |
645,832
+8,228
| +1% | +$107K |
|
1162
Interactive Brokers
IBKR
$41.4B
| $6.82M | ﹤0.01% |
222,396
+9,276
| +4% | +$277K |
|
1163
Agilon Health
AGL
$1.49B
| $6.81M | ﹤0.01% |
41,629
-25,001
| -38% | -$3.56M |
|
1164
AMN Healthcare
AMN
$1.34B
| $6.79M | ﹤0.01% |
132,609
-283,620
| -68% | -$16.1M |
|
1165
Ovintiv
OVV
$17.2B
| $6.75M | ﹤0.01% |
143,977
-907
| -0.6% | -$45.7K |
|
1166
Wolfspeed
WOLF
$1.64B
| $6.73M | ﹤0.01% |
295,841
+235,338
| +389% | +$6.09M |
|
|
HCP
1167
DELISTED
HashiCorp, Inc. Class A Common Stock
HCP
| $6.62M | ﹤0.01% |
196,447
-123,232
| -39% | -$3.83M |
|
1168
Neumora Therapeutics
NMRA
$321M
| $6.58M | ﹤0.01% |
669,486
-83,438
| -11% | -$863K |
|
1169
TD Synnex
SNX
$20.4B
| $6.58M | ﹤0.01% |
57,005
+24,245
| +74% | +$2.96M |
|
|
ETRN
1170
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
| $6.56M | ﹤0.01% |
505,154
+152,161
| +43% | +$2.04M |
|
1171
Brixmor Property Group
BRX
$9.21B
| $6.56M | ﹤0.01% |
283,879
+12,413
| +5% | +$275K |
|
1172
WisdomTree
WT
$3.44B
| $6.54M | ﹤0.01% |
660,069
+31,676
| +5% | +$298K |
|
1173
Timken Company
TKR
$9.1B
| $6.41M | ﹤0.01% |
79,931
-9,386
| -11% | -$810K |
|
1174
Grupo Cibest SA
CIB
$22.7B
| $6.26M | ﹤0.01% |
191,729
+10,448
| +6% | +$359K |
|
1175
Kemper
KMPR
$1.59B
| $6.23M | ﹤0.01% |
105,060
-1,298,444
| -93% | -$76.2M |
|
Similar funds
T. Rowe Price Associates's Q2 2024 Portfolio in Review
As of Q2 2024, T. Rowe Price Associates held 3,089 positions worth $836B, up 2.4% from $816B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
T. Rowe Price Associates's Q2 2024 filing shows 135 new, 1,850 increased, 836 reduced and 113 closed positions. Its largest new stake was Tempus AI: 5,227,120 shares worth $183M. The largest sale was Microsoft, an estimated $2.31B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2024 buy was Tempus AI: 5,227,120 shares worth $183M.
- T. Rowe Price Associates added most to Apple in Q2 2024, an estimated $4.01B increase.
- T. Rowe Price Associates's biggest Q2 2024 reduction was Microsoft, cutting an estimated $2.31B.
- T. Rowe Price Associates fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $570M.
- T. Rowe Price Associates's ten largest holdings make up 36% of its $836B portfolio in Q2 2024.
- T. Rowe Price Associates opened 135 new positions and closed 113 in Q2 2024.
- T. Rowe Price Associates's portfolio value rose 2.4% quarter-over-quarter to $836B.
Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.